{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:44:22Z","timestamp":1773827062680,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s10072-023-07182-0","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T02:01:33Z","timestamp":1699668093000},"page":"1619-1624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Progressive multifocal leukoencephalopathy in patients with chronic kidney disease"],"prefix":"10.1007","volume":"45","author":[{"given":"Jennifer","family":"Meylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Crespo","family":"Artunduaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam I.","family":"Hooshmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3549-3277","authenticated-orcid":false,"given":"Ahmed Z.","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"issue":"4","key":"7182_CR1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ncl.2018.06.002","volume":"36","author":"E Grebenciucova","year":"2018","unstructured":"Grebenciucova E, Berger JR (2018) Progressive multifocal leukoencephalopathy. Neurol Clin 36(4):739\u2013750. https:\/\/doi.org\/10.1016\/j.ncl.2018.06.002","journal-title":"Neurol Clin"},{"issue":"8","key":"7182_CR2","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1007\/s00415-020-10265-z","volume":"268","author":"PGE Kennedy","year":"2021","unstructured":"Kennedy PGE (2021) An overview of viral infections of the nervous system in the immunosuppressed. J Neurol 268(8):3026\u20133030. https:\/\/doi.org\/10.1007\/s00415-020-10265-z","journal-title":"J Neurol"},{"key":"7182_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","volume":"12","author":"JR Berger","year":"2017","unstructured":"Berger JR (2017) Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12:59\u201363. https:\/\/doi.org\/10.1016\/j.msard.2017.01.006","journal-title":"Mult Scler Relat Disord"},{"key":"7182_CR4","doi-asserted-by":"publisher","first-page":"7050613","DOI":"10.1155\/2016\/7050613","volume":"2016","author":"T Nanda","year":"2016","unstructured":"Nanda T (2016) Progressive multifocal leukoencephalopathy in a HIV negative, immunocompetent patient. Case Rep Neurol Med 2016:7050613. https:\/\/doi.org\/10.1155\/2016\/7050613","journal-title":"Case Rep Neurol Med"},{"issue":"3","key":"7182_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000354828","volume":"5","author":"KK Johansen","year":"2013","unstructured":"Johansen KK, Torp SH, Rydland J, Aasly JO (2013) Progressive multifocal leukoencephalopathy in an immunocompetent patient? Case Rep Neurol 5(3):149\u2013154. https:\/\/doi.org\/10.1159\/000354828","journal-title":"Case Rep Neurol"},{"issue":"1\u20132","key":"7182_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jns.2013.01.010","volume":"326","author":"PG Christakis","year":"2013","unstructured":"Christakis PG, Okin D, Huttner AJ, Baehring JM (2013) Progressive multifocal leukoencephalopathy in an immunocompetent patient. J Neurol Sci 326(1\u20132):107\u2013110. https:\/\/doi.org\/10.1016\/j.jns.2013.01.010","journal-title":"J Neurol Sci"},{"key":"7182_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/549271","volume":"2014","author":"VC Gourineni","year":"2014","unstructured":"Gourineni VC, Juvet T, Kumar Y, Bordea D, Sena KN (2014) Progressive multifocal leukoencephalopathy in a 62-year-old immunocompetent woman. Case Rep Neurol Med 2014:549271. https:\/\/doi.org\/10.1155\/2014\/549271","journal-title":"Case Rep Neurol Med"},{"issue":"3","key":"7182_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/jnnp.2009.187666","volume":"81","author":"S Gheuens","year":"2010","unstructured":"Gheuens S, Pierone G, Peeters P, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 81(3):247\u2013254. https:\/\/doi.org\/10.1136\/jnnp.2009.187666","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"7182_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1017\/cjn.2020.59","volume":"47","author":"BA Durafourt","year":"2020","unstructured":"Durafourt BA, Rossiter JP, Baharnoori M (2020) Unexpected progressive multifocal leukoencephalopathy in a hemodialysis patient. Can J Neurol Sci 47(5):727\u2013730. https:\/\/doi.org\/10.1017\/cjn.2020.59","journal-title":"Can J Neurol Sci"},{"issue":"15","key":"7182_CR10","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB et al (2013) PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80(15):1430\u20131438. https:\/\/doi.org\/10.1212\/WNL.0b013e31828c2fa1","journal-title":"Neurology"},{"issue":"6","key":"7182_CR11","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1002\/jmv.27493","volume":"94","author":"S Sriwastava","year":"2022","unstructured":"Sriwastava S, Khan E, Khalid SH, Kaur A, Feizi P (2022) Progressive multifocal leukoencephalopathy in an immunocompetent patient: a case report and review of literature. J Med Virol 94(6):2860\u20132869. https:\/\/doi.org\/10.1002\/jmv.27493","journal-title":"J Med Virol"},{"key":"7182_CR12","doi-asserted-by":"publisher","unstructured":"Murray A, Major I, Nestor N, Sblendorio D (2022) SARS-CoV-2 induced lymphopenia leading to novel PML infection. Neuroimmunol Rep 2 https:\/\/doi.org\/10.1016\/j.nerep.2022.100115","DOI":"10.1016\/j.nerep.2022.100115"},{"issue":"4","key":"7182_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s13365-018-0638-0","volume":"24","author":"R Aghoram","year":"2018","unstructured":"Aghoram R, Narayan SK (2018) Progressive multifocal leukoencephalopathy in idiopathic CD4+ lymphocytopenia. J Neurovirol 24(4):526\u2013528. https:\/\/doi.org\/10.1007\/s13365-018-0638-0","journal-title":"J Neurovirol"},{"issue":"1","key":"7182_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ackd.2019.01.004","volume":"26","author":"M Syed-Ahmed","year":"2019","unstructured":"Syed-Ahmed M, Narayanan M (2019) Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis 26(1):8\u201315. https:\/\/doi.org\/10.1053\/j.ackd.2019.01.004","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"7182_CR15","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2215\/CJN.00950208","volume":"3","author":"S Kato","year":"2008","unstructured":"Kato S, Chmielewski M, Honda H et al (2008) Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3(5):1526\u20131533. https:\/\/doi.org\/10.2215\/CJN.00950208","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"7182_CR16","first-page":"124","volume":"74","author":"S Kralova","year":"2010","unstructured":"Kralova S, Leva L, Toman M (2010) Changes in lymphocyte function and subsets in dogs with naturally occurring chronic renal failure. Can J Vet Res 74(2):124\u2013129","journal-title":"Can J Vet Res"},{"issue":"33","key":"7182_CR17","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1038\/sj.onc.1206559","volume":"22","author":"K Khalili","year":"2003","unstructured":"Khalili K, Del Valle L, Otte J, Weaver M, Gordon J (2003) Human neurotropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene 22(33):5181\u20135191. https:\/\/doi.org\/10.1038\/sj.onc.1206559","journal-title":"Oncogene"},{"issue":"2","key":"7182_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/13550289909021994","volume":"5","author":"R Caldarelli-Stefano","year":"1999","unstructured":"Caldarelli-Stefano R, Vago L, Omodeo-Zorini E et al (1999) Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. J Neurovirol 5(2):125\u2013133. https:\/\/doi.org\/10.3109\/13550289909021994","journal-title":"J Neurovirol"},{"key":"7182_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3389\/fimmu.2019.01188","volume":"10","author":"L Krey","year":"2019","unstructured":"Krey L, Raab P, Sherzay R et al (2019) Severe progressive multifocal leukoencephalopathy (PML) and spontaneous immune reconstitution inflammatory syndrome (IRIS) in an immunocompetent patient. Front Immunol 10:1188. https:\/\/doi.org\/10.3389\/fimmu.2019.01188","journal-title":"Front Immunol"},{"issue":"11","key":"7182_CR20","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1111\/ene.14434","volume":"27","author":"DB Clifford","year":"2020","unstructured":"Clifford DB (2020) Checkpoint therapy for progressive multifocal leukoencephalopathy: pointless? Eur J Neurol 27(11):2114\u20132116. https:\/\/doi.org\/10.1111\/ene.14434","journal-title":"Eur J Neurol"},{"issue":"5","key":"7182_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","volume":"72","author":"BO Khatri","year":"2009","unstructured":"Khatri BO, Man S, Giovannoni G et al (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72(5):402\u2013409. https:\/\/doi.org\/10.1212\/01.wnl.0000341766.59028.9d","journal-title":"Neurology"},{"issue":"Suppl 8","key":"7182_CR22","doi-asserted-by":"publisher","first-page":"S297","DOI":"10.21037\/atm.2019.11.11","volume":"7","author":"LM Juarez-Salcedo","year":"2019","unstructured":"Juarez-Salcedo LM, Dalia S (2019) Use of check-point inhibitors in the treatment of progressive multifocal leukoencephalopathy. Ann Transl Med 7(Suppl 8):S297. https:\/\/doi.org\/10.21037\/atm.2019.11.11","journal-title":"Ann Transl Med"},{"issue":"6","key":"7182_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/ana.26198","volume":"90","author":"R Bernard-Valnet","year":"2021","unstructured":"Bernard-Valnet R, Koralnik IJ, Du Pasquier R (2021) Advances in treatment of progressive multifocal leukoencephalopathy. Ann Neurol 90(6):865\u2013873. https:\/\/doi.org\/10.1002\/ana.26198","journal-title":"Ann Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07182-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T07:25:42Z","timestamp":1710487542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07182-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["7182"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07182-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None\u00a0related to this manuscript Dr. Ahmed Z. Obeidat has received personal compensation for participation in scientific advisory boards, steering committees, and\/or for speaking engagements from Alexion Pharmaceuticals, Banner Life Sciences, BD Biosciences, Biogen, Biologix Solutions, Bristol Myers Squibb, Celgene, EMD Serono, Genentech, GW Pharmaceuticals, Horizon Therapeutics, Jazz Pharmaceuticals, Novartis (local and global), Sandoz, Sanofi Genzyme, TG Therapeutics, and Viela Bio; has received consulting fee for serving as a scientific reviewer for the 2020 and 2022 Multiple Sclerosis Research Program (MSRP) for the Department of Defense Congressionally Directed Medical Research Programs (CDMRP); has received honoraria from Medscape, MJH Life Sciences, and WebMD; has served as a site principal investigator for studies funded (directly paid to Medical College of Wisconsin) by Atara Biotherapeutics, Biogen, Bristol Myers Squibb, Celgene, CorEvitas, EMD Serono, Genentech, GW Pharmaceuticals, Immunic Therapeutics, National Multiple Sclerosis Society\/Patient-Centered Outcomes Research Institute, Novartis, Sanofi Genzyme, and TScan Therapeutics; and has received research funds from Central for Immunology, Clinical & Translational Science Institute (CTSI), National Institutes of Health, Neuroscience Research Center, and Research Affairs Committee. Other authors have no disclosures to report. Dr. Sam I. Hooshmand has received personal compensation for participation in scientific advisory boards from Genetech and Sanofi Genzyme; has served as a site principal investigator for studies funded (directly paid to Medical College of Wisconsin) by EMD Serono, Novartis, and Sanofi Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}